Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma

Pharmacogenetics and Genomics

Volumn 17, Issue 9, 2007, Pages 709-717

  Ashton, Lesley J ^a   Murray, Jayne E ^a   Haber, Michelle ^a   Marshall, Glenn M ^a,b   Ashley, David M ^c   Norris, Murray D ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Neuroblastoma; Pediatric; Polymorphisms; Survival

Indexed keywords

ACYLTRANSFERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; NUCLEIC ACID BINDING PROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADOLESCENT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE-FREE SURVIVAL; DNA PRIMERS; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 34547888296     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3280e1cc92     Document Type: Article

References (64)

1. Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, et al. The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 1997; 33:2092-2097.
2. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59:1261-1277.
3. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Associations of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-1116.
4. Bourhis J, Dominici C, McDowell H, Raschella G, Wilson G, Castello MA, et al. N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol 1991; 9:1371-1375.
5. Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, et al. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet 1996; 97:834-837.
6. Tonini GP, Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer Lett 2003; 197:69-73.
7. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15:273-280.
8. Daly AK. Pharmacogenetics of the major polymorphic metabolising enzymes. Fund Clin Pharm 2003; 17:27-41.
9. Cosma G, Crofts F, Currie D, Wirgin I, Toniolo P, Garte SJ. Racial differences in the restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol Biomarkers Prev 1993; 2:53.
10. Cascorbi I, Brockmoller J, Roots I. AC4887A polymorphism in the exon 7 of human CYP1A1: population frequency, mutation linkages and impact on lung cancer susceptibility. Cancer Res 1996; 56:4965-4969.
11. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4:242-246.
12. Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002; 12:655-658.
13. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004; 43:560-567.
14. Doll MA, Hein DW. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal Biochem 2002; 301:328-332.
15. De Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1*. Mol Pharmacol 2000; 58:288-299.
16. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 & NAT2 acetylation polymorphisms. Cancer Epid Bio Prev 2000; 9:29-42.
17. Hein DW. Molecular Genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mut Res 2002; 506-507:65-77.
18. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C, et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate 2005; 64:246-252.
19. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione s-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300:271-276.
20. Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, et al. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol expoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997; 238:397-402.
21. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization and expression of Escherichia coli of full-length cDNAs of three human glutathione s-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272:10004-10012.
22. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994; 224:893-899.
23. Tew KD. Glutathionine-associated enzymes in anti-cancer drug resistance. Cancer Res 1994; 54:4313.
24. Zhang K, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998; 12:871-882.
25. Hall AG, Autzen P, Cattan AR, Malcolm AJ, Cole M, Kernahan J, et al. Expression of mu class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res 1994; 54:5251-5254.
26. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19:1279-1287.
27. Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61:7130-7135.
28. Autrup JL, Hokland P, Pedersen L, Autrup H. Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur J Pharmacol 2002; 438:15-18.
29. Dieckvoss BO, Stanulla M, Schrappe M, Beier R, Zimmermann M, Welte K, et al. Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin's lymphoma. Haematologica 2002; 87:709-713.
30. Voso MT, D'Alo' F, Putzulu R, Mele L, Scardocci A, Chiusolo P, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100:2703-2707.
31. Hohaus S, Massini G, D'Alo' F, Guidi F, Putzulu R, Scardocci A, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003; 9:3435-3440.
32. Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, et al. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 2006; 28:231-236.
33. Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006; 94:281-286.
34. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100:330-337.
35. Bernard JL, Philip T, Zucker JM, Frappaz D, Robert A, Margueritte G, et al. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/ doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen? J Clin Oncol 1987; 5:1952-1959.
36. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin and total body irradiation. J Clin Oncol 1995; 13:2789-2795.
37. Norris MD, Haber M, Gilbert J, Kavallaris M, Marshall GM, Stewart BW. N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction. Prog Clin Biol Res 1994; 385:27-33.
38. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995; 55:3537-3542.
39. Boissy RJ, Watson MA, Umbach DM, Deakin M, Elder J, Strange RC, et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer 2000; 87:507-511.
40. Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8:55-66.
41. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58: 1759-1764.
42. Kukongviriyapan V, Prawan A, Warasiha B, Tassaneyakul W, Aiemsa-ard J. Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population. Eur J Clin Pharmacol 2003; 59:277-281.
43. Garte S, Gaspari L, Alexandrie A, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10:1239-1248.
44. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6:733-743.
45. Ezer R, Alonso M, Pereira E, Kim M, Allen JC, Miller DC, et al. Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J Neurooncol 2002; 59:123-134.
46. Cascorbi I, Roots I, Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001; 61:5051-5056.
47. Zheng W, Deitz AC, Campbell DR, Wen WQ, Cerhan JR, Sellers TA, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:33-39.
48. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3039-3047.
49. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, et al. Arlylamine N-Acetyltranferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003; 1:826-835.
50. Geylan-Su YS, Isgor B, Coban T, Kapucuoglu N, Aydintug S, Iscan M, et al. Comparison of NAT1, NAT2, & GSTT2-2 activities in normal and neoplastic human breast tissues. Neoplasma 2006; 53:73-78.
51. Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Publ 1999; 148:251-270.
52. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 1997; 233:584-591.
53. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 1997; 253:219-224.
54. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10:715-726.
55. Stanulla M, Schrappe M, Muller Brechlin A, Zimmerman M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and the risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000; 95:1222-1228.
56. Takanashi M, Morimoto A, Yagi T, Kuriyama K, Kano G, Imamura T, et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Hematologica 2003; 8:238-244.
57. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002; 100:67-71.
58. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Canc Res 2002; 8:802-810.
59. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-942.
60. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 2002; 16:203-208.
61. Howells RE, Redman CW, Dhar KK, Sarhanis P, Musgrove C, Jones PW, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1998; 4:2439-2445.
62. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996; 56:3577-3582.
63. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22:7369-7375.
64. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117-129.